SAM
NBIX icon

Senzar Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Senzar Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-749,200
Closed -$34.5M – 34
2017
Q2 		$34.5M Buy
+749,200
New +$36.3M 8.49% 4

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Senzar Asset Management's NBIX Position: Q3 2017 in Review

Senzar Asset Management sold out of Neurocrine Biosciences (NBIX) in Q3 2017, closing a stake of 749,200 shares — an estimated $34.5M sold.

Senzar Asset Management first reported a position in NBIX in Q2 2017 and held it in 1 quarter. The position peaked at $34.5M in Q2 2017. 223 funds tracked by Wall St. Rank hold NBIX as of Q3 2017.

  • Senzar Asset Management reported no remaining Neurocrine Biosciences position as of Q3 2017 after selling out during the quarter.
  • Senzar Asset Management sold 749,200 Neurocrine Biosciences shares in Q3 2017, an estimated $34.5M.
  • Senzar Asset Management first reported a position in Neurocrine Biosciences in Q2 2017 and held it in 1 quarter.
  • Senzar Asset Management's Neurocrine Biosciences position peaked at $34.5M in Q2 2017.
  • 223 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2017.

Based on Senzar Asset Management's 13F filing for Q3 2017, filed 13 Nov 2017.